GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Buildings And Improvements

MindBio Therapeutics (XCNQ:MBIO) Buildings And Improvements : C$0.00 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Buildings And Improvements?


MindBio Therapeutics Buildings And Improvements Historical Data

The historical data trend for MindBio Therapeutics's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Buildings And Improvements Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Buildings And Improvements
- - -

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MindBio Therapeutics Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus

Mustang Bio to Participate in the B. Riley Securities' 3rd Annual Oncology Conference

By Stock market mentor Stock market mentor 01-17-2023